Alkem Labs Cuts Diabetes Drug Cost by 80% with Empanorm Launch
Written by Sirish Dixit
Alkem Labs introduces Empanorm, an affordable generic empagliflozin, reducing costs by 80% and enhancing diabetes care with patient-friendly features.
Alkem Laboratories Ltd has launched Empanorm, a generic version of empagliflozin, along with its combinations, in India at prices nearly 80% lower than the original innovator products. Empagliflozin, an SGLT-2 inhibitor, is widely used for managing type-2 diabetes, chronic kidney disease (CKD), and chronic heart failure (HF). These generic formulations are bioequivalent to their innovator counterparts, ensuring effective treatment at an affordable cost.
With a patient-centric approach, Alkem has integrated an anti-counterfeit security band on Empanorm’s packaging and included diabetes education materials in Hindi and English. The pack also features QR codes that provide prescribing details and additional educational resources in 11 languages. Additionally, Empanorm tablets are available in a smaller size, enhancing patient convenience.
The generic empagliflozin is marketed under Empanorm, while its combinations include:
- Empanorm L (empagliflozin + linagliptin)
- Empanorm Duo / Alsita E (empagliflozin + sitagliptin)
- Empanorm M (empagliflozin + metformin)
Dr. Vikas Gupta, CEO of Alkem, emphasized that this launch is a significant milestone in expanding the company's chronic care portfolio. With its strong distribution network, Alkem aims to increase accessibility to this globally accepted therapy, improving diabetes and cardiovascular health outcomes across India.